TRIMT

Executive Summary

TRIMT GmbH is a Berlin-based biotechnology company established in 2018, specializing in the development of targeted radiopharmaceuticals for molecular theranostics of cancer. The company integrates diagnostic and therapeutic capabilities to address high unmet clinical needs, leveraging a proprietary intellectual property portfolio and a science-driven approach. Currently operating at the pre-clinical stage, TRIMT is positioned to advance its pipeline of targeted radioligands for various solid tumors, with a focus on precision medicine and personalized treatment strategies. As a private company with limited public disclosures, TRIMT has not yet disclosed total funding or valuation details. Its progress will depend on successful pre-clinical validation, potential partnerships with larger radiopharmaceutical firms, and regulatory milestones such as IND filings. The company operates in a highly competitive but rapidly growing radiopharmaceutical field, where theranostic pairs (e.g., targeting PSMA, SSTR2) have shown clinical promise. TRIMT's differentiation may rely on novel targets or improved pharmacokinetics. Near-term value inflection points include securing Series A financing, initiating first-in-human studies, or announcing collaborations.

Upcoming Catalysts (preview)

• 2026Series A Financing Round60% success
• 2027Lead Candidate IND Filing40% success
• 2026Research Partnership or Licensing Deal50% success